Article Sidebar

Download
PDF
Statistic
Read Counter : 670 Download : 650

Main Article Content

Abstract

Ocular involvement in Anti Phospolipid Syndrome (APS) includes a broad spectrum of manifestations from the anterior and posterior segment or the presence of neuro-ophthalmologic features. A female, 29 years old, came to ER handled by ophthalmology department, with chief complaint left visual loss suddenly since 4 hours before admission. Investigations revealed stable vital signs, VOD 20/20, VOS 1/300, funduscopy showed
pale and cherry red spot on left retina, OCT revealed hyperreflective of left inner retinal layer, IgG aCL 51.7 U/mL (50.8 U/mL in OPD 3 months later), and the other examinations were within normal limit. Patient was diagnosed with Central Retinal Artery Occlusion due to
Primary Antiphospolipid syndrome. She was performed occular massage and anterior chamber paracintesis procedure, and given O2 6-8 lpm NRBM, Timolol 0.5% eye drop left eye bid, acetazolamide 250 mg bid, Kalium Slow Release 1 tab qd, Levofloxacine eye drop 1 drop/
hour post surgery. After the result of IgM aCL available, we added warfarin 2 mg qd and aspirin 320 mg qd. Patient was discharged 2 days later as visual acuity improved with VOD 20/20 and VOS 0.5/60.

Key words: Central retina artery occlusion, primary anti phospolipid syndrome, anti cardiolipin antibody

Article Details

How to Cite
Trianto, H. B., Wahono, C. S., & Dewi, N. A. (2018). A Successful Management of 29 year old Female with Left Central Retinal Artery Occlusion due to Manifestation of Primary Antiphospholipid Syndrome. Indonesian Journal of Rheumatology, 8(2). https://doi.org/10.37275/ijr.v8i2.61

References

  1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemostasis. 2006; 4(2):295-306.
  2. Dalekos GN, Zachou K, Liaskos C. The antiphospholipid syndrome and infection. Curr Rheumatol Rep. 2001; 3: 277-285.
  3. Khamashta MA, Bertolaccini ML, Hughes GR. Antiphospholipid (Hughes) syndrome. Autoimmunity. 2004; 37:309-312.
  4. Cabrita FVL, Foster CS. Anticardiolipin antibodies and ocular disease. Ocul Immunol Inflamm. 2005; 13:265-270.
  5. Giorgio D, Gabrieli CB, Bonomo L. The clinico-ophthalmological spectrum of antiphospholipid syndrome. Ocul Immunol Inflamm. 1998; 6:269-273.
  6. Kalogeropoulos CD, Spyrou P, Stefaniotou MI, Tsironi EE, Drosos AA, Psilas KG. Anticardiolipine antibodies and occlusive vascular disease of the eye: a prospective study. Doc Ophthalmol. 1998; 2:109-112.
  7. Davila L, Joseph A, editor. Rheumatology subspeciality consult: anti phospolipid syndrome. 2nd Edition. Phyladelphia: Lippincott Williams &Wilkins: 2012, 39:329-335.
  8. Rand JH. Molecular pathogenesis of the antiphospolipid syndrome. Circ Res. 2002; 90:29-37.
  9. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. JAMA. 2006; 295 (9): 1050-1057.
  10. Keeling D, Mackie I, Moore GW, Greer IA, Greaves M. Guidelines on the investigation and management of antiphospolipid syndrome. British Journal of Hematology. 2012; 157: 47-58.
  11. Cobo-Soriano R, Sanchez-Ramon S, Aparicio MJ, Teijeiro MA, Vidal P, Suárez-Leoz M, et al. Andiphospholipid antibodies and retinal thrombosis in patients without risk factors: a prospective case-control study. Am J Ophthalmol. 1999; 6:725-732.
  12. Miserocchi E, Baltatzis S, Foster CS: Ocular features associated with anticardiolipin antibodies. Am J Ophthalmol. 2001;131:451-456.
  13. Bolling JP, Brown GC: The antiphospholipid antibody syndrome. Curr Opin Ophthalmol. 2000;11:211-213.
  14. Tsironi E, Gatselis N, Kotoula MG, Chatzoulis DZ, Dalekos GN: Unxplained choroidal embolization: remember the antiphospholipid syndrome. Lancet. 2006; 368:1936.
  15. Marcucci R, Sodi A, Giambene B, Liotta AA, Poli D, Mannini L, Falciani M, Abbate R, Menchini U, Prisco D: Cardiovascular and thrombophilic risk factors in patients with retinal artery occlusion. Blood Coag Fibrin. 2007;18:321-326.
  16. Cahill M, Stinnett SS, Fekrat S: Meta-analysis of plasma homocysteine, serum folate, serum vitamin B12 and thermolabile MTHFR genotype as risk factors for retinal vascular occlusive disease. Am J Ophthalmol. 2003; 136:1136-1150.
  17. Miyakis S. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). JThromb haemost. 2006; 4:295–306.
  18. Graham RH. Central Retinal Artery Occlusion. Opthlmology. 1980 Jan; 87 (1):75-78